Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SX-682 + decitabine
- Development stage
- Unknown
- Lead developer
- Syntrix Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of **SX-682** and **decitabine** is being investigated for the treatment of myelodysplastic syndromes (MDS). **SX-682** is a small molecule inhibitor targeting the chemokine receptors **CXCR1** and **CXCR2**, potentially reducing tumor-promoting inflammation and cellular migration. **Decitabine** is an FDA-approved DNA methylation inhibitor that acts as a hypomethylating agent by inhibiting **DNA methyltransferases**, leading to decreased DNA methylation and reactivation of tumor suppressor genes. This combination targets distinct pathogenic mechanisms in MDS, combining epigenetic modulation with chemokine receptor antagonism[1][2][5].
- Other names
- 5-aza-2'-deoxycytidine
02
Targets
DNMT1 (DNA (cytosine-5)-methyltransferase 1)CXCR1 (C-X-C chemokine receptor 1)DNMT3A (DNA methyltransferase 3 alpha)CXCR2 (C-X-C Motif Chemokine Receptor 2)DNMT3B (DNA (cytosine-5)-methyltransferase 3B)
Beyond the preview
Go deeper on SX-682 + decitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SX-682 + decitabine.